Ask AI
ProCE Banner Activity

Applying CDK4/6 Inhibitors in High-Risk Early HR+/HER2- Breast Cancer: A Case-Based Discussion

Clinical Thought

Check out our case discussion to gain insights to help you optimize adjuvant CDK4/6 inhibitor therapy for your patients with hormone receptor–positive/HER2-negative early-stage breast cancer based on the latest available evidence.

Released: November 06, 2025

Share

Provided by

Provided by Partners for Advancing Clinical Education (Partners) in partnership with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Lilly.

Lilly

Partners

Clinical Care Options, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Elizabeth Diaz, PA-C, has no relevant financial relationships to disclose.

Julia LaBarbera, MSN, RN, AGACNP-BC: consultant/advisor/speaker: AstraZeneca, Daiichi Sankyo.